retatrutide phase 2 trial obesity nejm 2023 triple agonist 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending retatrutide phase 2 trial obesity

The regulatory status of BPC-157 varies by country: it is not approved as a medication but remains accessible as a research peptide in certain jurisdictions

Healthy Directions has more on what they are and what they do

doi: 10.1016/j.ejphar.2004.02.049

Studies show that temperature-damaged medications produce weaker hunger suppression and slower weight loss than properly stored doses

[DOI] [PMC free article] [PubMed] [Google Scholar] 121.Saez-Lopez C., Villena J.A., Simo R., Selva D.M

Analysis of the D dhar mutant showed that DHARs are required to couple hydrogen peroxide metabolism to glutathione oxidation, and that this is functionally important for downstream activation of the salicylic acid pathway